Heart Ebitda from 2010 to 2024

HSCS Stock  USD 2.67  0.05  1.91%   
Heart Test EBITDA yearly trend continues to be comparatively stable with very little volatility. EBITDA will likely drop to about -6.5 M in 2024. From the period from 2010 to 2024, Heart Test EBITDA quarterly data regression had mean square error of 886.3 B and mean deviation of  852,904. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-6.2 M
Current Value
-6.5 M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Heart Test financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Heart Test's main balance sheet or income statement drivers, such as Depreciation And Amortization of 58.5 K, Interest Expense of 242.9 K or Selling General Administrative of 2.5 M, as well as many indicators such as Price To Sales Ratio of 349, Dividend Yield of 0.0 or PTB Ratio of 0.42. Heart financial statements analysis is a perfect complement when working with Heart Test Valuation or Volatility modules.
  
Check out the analysis of Heart Test Correlation against competitors.

Latest Heart Test's Ebitda Growth Pattern

Below is the plot of the Ebitda of Heart Test Laboratories over the last few years. It is Heart Test's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Heart Test's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Heart Ebitda Regression Statistics

Arithmetic Mean(4,184,321)
Coefficient Of Variation(27.38)
Mean Deviation852,904
Median(3,734,464)
Standard Deviation1,145,811
Sample Variance1.3T
Range4.2M
R-Value(0.61)
Mean Square Error886.3B
R-Squared0.37
Significance0.02
Slope(156,502)
Total Sum of Squares18.4T

Heart Ebitda History

2024-6.5 M
2023-6.2 M
2022-6.1 M
2021-4.4 M
2020-2.3 M

About Heart Test Financial Statements

Heart Test shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although Heart Test investors may analyze each financial statement separately, they are all interrelated. The changes in Heart Test's assets and liabilities, for example, are also reflected in the revenues and expenses on on Heart Test's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-6.2 M-6.5 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Heart Stock Analysis

When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.